Hansa Biopharma AB (publ) (HNSBF)
HNSBF Stock Price Chart
Explore Hansa Biopharma AB (publ) interactive price chart. Choose custom timeframes to analyze HNSBF price movements and trends.
HNSBF Company Profile
Discover essential business fundamentals and corporate details for Hansa Biopharma AB (publ) (HNSBF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Mar 2015
Employees
138.00
Website
https://www.hansabiopharma.comCEO
Renee Aguiar-Lucander
Description
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
HNSBF Financial Timeline
Browse a chronological timeline of Hansa Biopharma AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 23 Oct 2025
Earnings released on 17 Jul 2025
EPS came in at -$0.26 falling short of the estimated -$0.17 by -51.17%, while revenue for the quarter reached $5.13M , missing expectations by -91.88%.
Earnings released on 24 Apr 2025
EPS came in at -$0.05 surpassing the estimated -$0.27 by +79.41%, while revenue for the quarter reached $6.63M , missing expectations by -90.59%.
Earnings released on 6 Feb 2025
EPS came in at -$0.37 falling short of the estimated -$0.18 by -105.79%, while revenue for the quarter reached $2.91M , missing expectations by -96.26%.
Earnings released on 17 Oct 2024
EPS came in at -$0.16 surpassing the estimated -$0.24 by +32.88%, while revenue for the quarter reached $4.69M , missing expectations by -11.71%.
Earnings released on 18 Jul 2024
EPS came in at -$0.31 falling short of the estimated -$0.26 by -19.74%, while revenue for the quarter reached $3.25M , missing expectations by -36.25%.
Earnings released on 18 Apr 2024
EPS came in at -$0.38 falling short of the estimated -$0.32 by -18.40%, while revenue for the quarter reached $5.16M , beating expectations by +2.27%.
Earnings released on 28 Feb 2024
EPS came in at -$0.23 surpassing the estimated -$0.37 by +36.30%, while revenue for the quarter reached $4.99M , beating expectations by +14.65%.
Earnings released on 30 Sept 2023
EPS came in at -$0.43 falling short of the estimated -$0.36 by -19.68%, while revenue for the quarter reached $2.07M , missing expectations by -44.74%.
Earnings released on 30 Jun 2023
EPS came in at -$0.44 falling short of the estimated -$0.33 by -34.91%, while revenue for the quarter reached $3.38M , missing expectations by -7.26%.
Earnings released on 31 Mar 2023
EPS came in at -$0.38 falling short of the estimated -$0.28 by -34.63%, while revenue for the quarter reached $2.32M , missing expectations by -26.56%.
Earnings released on 31 Dec 2022
EPS came in at -$0.31 surpassing the estimated -$0.40 by +20.40%, while revenue for the quarter reached $3.00M , beating expectations by +1.44%.
Earnings released on 30 Sept 2022
EPS came in at -$0.31 falling short of the estimated -$0.17 by -80.81%, while revenue for the quarter reached $5.99M , beating expectations by +126.56%.
Earnings released on 30 Jun 2022
EPS came in at -$0.37 falling short of the estimated -$0.18 by -103.47%, while revenue for the quarter reached $2.57M , beating expectations by +41.01%.
Earnings released on 31 Mar 2022
EPS came in at -$0.33 , while revenue for the quarter reached $3.23M .
Earnings released on 31 Dec 2021
EPS came in at -$0.40 falling short of the estimated -$0.38 by -5.63%, while revenue for the quarter reached $1.70M , beating expectations by +1.30%.
Earnings released on 30 Sept 2021
EPS came in at -$0.38 , while revenue for the quarter reached $563.40K .
Earnings released on 30 Jun 2021
EPS came in at -$0.35 , while revenue for the quarter reached $528.58K .
Earnings released on 31 Mar 2021
EPS came in at -$0.27 , while revenue for the quarter reached $1.03M .
Earnings released on 31 Dec 2020
EPS came in at -$0.29 , while revenue for the quarter reached $464.62K .
Earnings released on 30 Sept 2020
EPS came in at -$0.31 , while revenue for the quarter reached $85.15K .
HNSBF Stock Performance
Access detailed HNSBF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.